Načítá se...
IL1-blocking therapy in colchicine-resistant familial Mediterranean fever
OBJECTIVE: Approximately 10%–20% of patients with familial Mediterranean fever (FMF) show an inadequate response to colchicine. In our cohort study, patients with FMF with or without amyloidosis and with an inadequate response to colchicine were treated with anakinra or canakinumab. METHODS: Clinica...
Uloženo v:
| Vydáno v: | Eur J Rheumatol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Medical Research and Education Association
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6267760/ https://ncbi.nlm.nih.gov/pubmed/30501849 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5152/eurjrheum.2018.18036 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|